+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV)



Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV)



Journal of Proteome Research 10(2): 774-779



Only half of chronic hepatitis C (CH-C) patients treated with pegylated interferon and ribavirin (PEG-IFN+RBV) achieve sustained virologic response) SVR. In addition to known factors, we postulated that activation of key protein signaling networks in the peripheral blood mononuclear cells (PBMCs) may contribute to SVR due to inherent patient-specific basal immune cell signaling architecture. In this study, we included 92 patients with CH-C. PBMCs were collected while patients were not receiving treatment and used for phosphoprotein-based network profiling. Patients received a full course of PEG-IFN+RBV with overall SVR of 55%. From PBMC, protein lysates were extracted and then used for Reverse Phase Protein Microarray (RPMA) analysis, which quantitatively measured the levels of cytokines and activation levels of 25 key protein signaling molecules involved in immune cell regulation and interferon alpha signaling. Regression models for predicting SVR were generated by stepwise bidirectional selection. Both clinical-laboratory and RPMA parameters were used as predictor variables. Model accuracies were estimated using 10-fold cross-validation. Our results show that by comparing patients who achieved SVR to those who did not, phosphorylation levels of 6 proteins [AKT(T308), JAK1(Y1022/1023), p70 S6 Kinase (S371), PKC zeta/lambda(T410/403), TYK2(Y1054/1055), ZAP-70(Y319)/Syk(Y352)] and overall levels of 6 unmodified proteins [IL2, IL10, IL4, IL5, TNF-alpha, CD5L] were significantly different (P < 0.05). For SVR, the model based on a combination of clinical and proteome parameters was developed, with an AUC = 0.914, sensitivity of 92.16%, and specificity of 85.0%. This model included the following parameters: viral genotype, previous treatment status, BMI, phosphorylated states of STAT2, AKT, LCK, and TYK2 kinases as well as steady state levels of IL4, IL5, and TNF-alpha. In conclusion, SVR could be predicted by a combination of clinical, cytokine, and protein signaling activation profiles. Signaling events elucidated in the study may shed some light into molecular mechanisms of response to anti-HCV treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055252191

Download citation: RISBibTeXText

PMID: 21204552

DOI: 10.1021/pr100923u


Related references

Protein Pathway Biomarkers Predicting Sustained Virologic Response (Svr) to Pegylated Interferon (Peg-Ifn) and Ribavirin (Rbv) in Treatment-Naive Genotype 1 Patients With Chronic Hepatitis C (Ch-C). Gastroenterology 138(5): S-783, 2010

Su1077 Vitamin D and B12 Supplementation and Sustained Virologic Response in Chronic Hepatitis C Patients Treated With Pegylated Interferon and Ribavirin. Gastroenterology 146(5): S-982, 2014

W1005 Hcv Rna At 12 Weeks After Treatment Can Predict Sustained Virologic Response in Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin. Gastroenterology 134(4): A-830, 2008

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Acta Biochimica Polonica 59(3): 333-337, 2013

M1781 Rapid Virologic Response Predicts Sustained Virologic Response in Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin Therapy. Gastroenterology 136(5): A-836-A-837, 2009

Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin. Zhonghua Gan Zang Bing Za Zhi 24(3): 175-180, 2017

High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. Bratislavske Lekarske Listy 110(2): 77-84, 2009

Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 30(5): 487-494, 2010

IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 39(5): 576-583, 2016

A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate. Clinical Infectious Diseases 58(1): 130-133, 2014

Is sustained virologic response durable in patients with chronic hepatitis C treated with interferon alfa with or without ribavirin?. Journal of Hepatology 36(Suppl. 1): 103, 2002

Su1074 Meta-Analysis: Sustained Virologic Response (Svr) in Patients With Infection With Hepatitis C Virus Genotype 5 (Hcv-5) Versus Genotype 1 (Hcv-1) and Hcv Genotype 2/3 (Hcv -2/3) Treated With Interferon (Ifn) or Pegylated Interferon and Ribavirin (Peg Ifn+Rbv). Gastroenterology 146(5): S-981-S-982, 2014

PEG-INTERFERON alpha-2B + RIBAVIRIN FOR TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO HAVE PREVIOUSLY FAILED TO ACHIEVE A SUSTAINED VIROLOGIC RESPONSE FOLLOWING INTERFERON ALFA OR INTERFERON A-2B + RIBAVIRIN THERAPY. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1292, 2003

Meta-Analysis: Sustained Virologic Response (Svr) in Asian Patients With Infection With Hepatitis C Virus Genotype 6 (Hcv-6) Versus Genotype 1 (Hcv-1) Treated With Pegylated Interferon and Ribavirin (Peg Ifn+Rbv) for 48 Weeks. Gastroenterology 146(5): S-921-S-922, 2014

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. Korean Journal of Hepatology 17(3): 183-188, 2012